You can reach us via e-mail 24/7 and get detailed information.Write US
Paxman has been pioneering scalp cooling technology for more than 20 years. We are proud to be the leading global experts in scalp cooling. The Paxman Scalp Cooling System is globally recognized as the leading product for hair-loss prevention during chemotherapy treatment.
The NCCN Guidelines now recommend scalp cooling as a category 2A treatment option for patients with invasive breast cancer The National Comprehensive Cancer Network® (NCCN®) has updated the Clinical Practice Guidelines in oncology for breast cancer (Version 1.2019) to include scalp cooling as a Category 2A recommendation to reduce the incidence of chemotherapy-induced alopecia for patients receiving chemotherapy.
Scalp cooling is a simple procedure that can prevent alopecia caused by certain chemotherapy drugs.
The use of scalp cooling is proven to be an effective way of combating CIA and can result in a high level of retention or can completely preserve the hair2. For patients, this means the opportunity to regain some control, maintain their privacy, and encourage a positive attitude toward treatment.
Chemotherapy works by targeting all rapidly dividing cells in the body. Hair is the second fastest dividing cell in the body and this is the reason why many chemotherapy drugs cause hair loss. The hair follicles in the growth phase are attacked resulting in hair loss approximately 2 weeks after the commencement of the chemotherapy treatment.
The basic principle of chemotherapy is to damage the mitotic and metabolic processes in cancer cells. The reason this also affects hair follicles is because as many as 90% of them will be in an active growth phase (anagen).
Chemotherapy induces keratinocyte apoptosis and hair follicle regression, as well as the impaired metabolic and mitotic processes in anagen hair follicles, all of which results in rapid and extensive alopecia.